Nuvectis, Public Offering
Nuvectis Pharma Announces Proposed Public Offering of Common Stock
Nuvectis intends to use the net proceeds from this offering to continue to advance the development programs of NXP800 and NXP900 or any future product candidate, hiring of additional personnel, capital expenditures, costs of operating as a public company and other general corporate purposes.
Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering
Glucot (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the pricing of a “best efforts” public offering of approximately 2.
China’s bubble tea company Guming Holdings has announced plans to raise up to HK1.58 billion (US$200 million) through an ...
The closing of the Offering is expected to occur on or about February 7, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds from the Offering are expected to be ...
NEW YORK (AP) — The following is a list of initial public offerings planned for the coming week. Sources include IPO ETF manager Renaissance Capital, and SEC filings. Week of Feb. 3 Titan ...
Akero Therapeutics announced a public offering of over 5.3 million shares at $48 each, aiming for $350 million in proceeds. Akero Therapeutics, Inc. has announced a public offering of 5,333,420 ...
Facebook (FB), now Meta Platforms Inc. (META), went public with its initial public offering (IPO) on May 18, 2012. The popular social networking company had one of the largest and most ...
Investing.com -- Immunome, Inc. (NASDAQ:IMNM) shares fell sharply by 9.6% following the announcement of the pricing of its upsized public offering of common stock. The biotechnology company ...
In connection with the proposed offering, Immunome expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback